Cargando…

Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells

BACKGROUND: Chimeric antigen receptor-engineered T (CAR-T) cells have extraordinary effect in treating lymphoblastic leukemia. However, treatment of acute myeloid leukemia (AML) using CAR-T cells remains limited to date. Leukemogenesis always relates with the abnormalities of cytogenetics, and nearl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ying, Xu, Yingxi, Li, Saisai, Liu, Jia, Xing, Yanyan, Xing, Haiyan, Tian, Zheng, Tang, Kejing, Rao, Qing, Wang, Min, Wang, Jianxiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930553/ https://www.ncbi.nlm.nih.gov/pubmed/29716633 http://dx.doi.org/10.1186/s13045-018-0603-7

Ejemplares similares

Correction: Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells
por: Chen, Nianci, et al.
Publicado: (2022)

Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells
por: Chen, Nianci, et al.
Publicado: (2021)

Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells
por: An, Na, et al.
Publicado: (2016)

2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies
por: Xu, Yingxi, et al.
Publicado: (2019)

Hyperfunction of CD4 CD25 regulatory T cells in de novo acute myeloid leukemia
por: Wan, Yuling, et al.
Publicado: (2020)

RUNX1 inhibits proliferation and induces apoptosis of t(8;21) leukemia cells via KLF4-mediated transactivation of P57
por: Liu, Shuang, et al.
Publicado: (2019)

FHL2 interacts with iASPP and impacts the biological functions of leukemia cells
por: Lu, Wenting, et al.
Publicado: (2017)

AML1-ETO-Related Fusion Circular RNAs Contribute to the Proliferation of Leukemia Cells
por: Wang, Ying, et al.
Publicado: (2022)

A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy
por: Zhang, Yu, et al.
Publicado: (2022)

Targeting FLT3 by Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
por: Chen, Lichao, et al.
Publicado: (2017)

Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity
por: Wang, Zhenzhen, et al.
Publicado: (2023)

A novel fusion protein TBLR1-RARα acts as an oncogene to induce murine promyelocytic leukemia: identification and treatment strategies
por: Li, Shouyun, et al.
Publicado: (2021)

Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3-mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia
por: Niswander, Lisa M., et al.
Publicado: (2022)

Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
por: Fan, Mingxue, et al.
Publicado: (2017)

Chimeric antigen receptor-modified T-cell therapy for bone marrow and skin relapse Philadelphia chromosome-like acute lymphoblastic leukemia: A case report
por: Yang, Mianzeng, et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy in acute myeloid leukemia
por: Koedam, Jan, et al.
Publicado: (2022)

Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
por: Hofmann, Susanne, et al.
Publicado: (2019)

Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia
por: Marvin-Peek, Jennifer, et al.
Publicado: (2022)

Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia
por: Schorr, Christopher, et al.
Publicado: (2022)

FLT3 inhibitors in acute myeloid leukemia
por: Wu, Mei, et al.
Publicado: (2018)

Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells
por: Klaihmon, Phatchanat, et al.
Publicado: (2023)

Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia
por: Maucher, Marius, et al.
Publicado: (2021)

Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
por: Le, Quy, et al.
Publicado: (2021)

Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations
por: Garg, Swati, et al.
Publicado: (2023)

Identification of JL1037 as a novel, specific, reversible lysine-specific demethylase 1 inhibitor that induce apoptosis and autophagy of AML cells
por: Liu, Shuang, et al.
Publicado: (2017)

Targeting FLT3 Mutations in Acute Myeloid Leukemia
por: El Fakih, Riad, et al.
Publicado: (2018)

Potential targeting of FLT3 acute myeloid leukemia
por: Ambinder, Alexander J., et al.
Publicado: (2020)

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia
por: Ma, Gina, et al.
Publicado: (2018)

FLT3-ITD Mutation and FLT3 Ligand Plasma Level Were Not Associated with One-Year Survival of Indonesian Acute Myeloid Leukemia Patients
por: Rinaldi, Ikhwan, et al.
Publicado: (2021)

Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T Cells Successfully Target Flt3 on AML Cell Lines
por: Maiorova, Varvara, et al.
Publicado: (2021)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
por: Xu, Dan, et al.
Publicado: (2022)

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
por: Gong, Ying, et al.
Publicado: (2021)

Engineering Chimeric Antigen Receptors
por: Kulemzin, S. V., et al.
Publicado: (2017)

Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia
por: Driouk, Lina, et al.
Publicado: (2020)

Selectively targeting FLT3-ITD mutants over FLT3- wt by a novel inhibitor for acute myeloid leukemia
por: Wang, Aoli, et al.
Publicado: (2020)

Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia
por: Gebru, Melat T., et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?
por: Cummins, Katherine D., et al.
Publicado: (2019)

Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression
por: Zhang, Dengyang, et al.
Publicado: (2021)

Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy
por: Chen, Manling, et al.
Publicado: (2023)

OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia
por: Eisfelder, Bartholomew J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v0c7nkvhfsrkq5q6koo4k0ns6e